Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis

doi:10.5493/wjem.v14.i4.98543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2251)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

HTML

1672

Figures (1-3)

Tables (1-1)

Sum=1840

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

126

Sum=189

Publishing Process of This Article

Item

Count

Browse

Download

Sum=58

Dec 20, 2024 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Exp Med. Dec 20, 2024; 14(4): 98543
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.98543

Open in New Tab Full Size Figure Download Figure

Figure 1 Preferred Reporting Items for Systematic Review and Meta-Analysis flow diagram of the search strategy.

Open in New Tab Full Size Figure Download Figure

Figure 2 Forest plot. A: The risk difference of hepatocellular carcinoma among MASLD patients between statin users versus non-users; B: The risk difference of hepatocellular carcinoma among users of lipophilic versus hydrophilic statins; C: The dose-dependent risk reduction of hepatocellular carcinoma among statin users. cDDD: Cumulative defined daily doses.

Open in New Tab Full Size Figure Download Figure

Figure 3 Funnel plot for publication bias.

Citation: Tarar ZI, Farooq U, Inayat F, Basida SD, Ibrahim F, Gandhi M, Nawaz G, Afzal A, Chaudhary AJ, Kamal F, Ali AH, Ghouri YA. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis. World J Exp Med 2024; 14(4): 98543
URL: https://www.wjgnet.com/2220-315x/full/v14/i4/98543.htm
DOI: https://dx.doi.org/10.5493/wjem.v14.i4.98543